Proteins

UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation

Retrieved on: 
Monday, September 6, 2021
Health, Genetics, General Health, Pharmaceutical, Optical, Biotechnology, Branches of biology, Leber's hereditary optic neuropathy, Proteins, Optic neuropathy, Mitochondrial disease, MT-ND6, Mitochondrial optic neuropathies, GenSight Biologics, Leber Hereditary Optic Neuropathy (LHON), LUMEVOQ® (GS010; lenadogene nolparvovec), the Early Access to Medicines Scheme (EAMS), GENSIGHT BIOLOGICS, LEBER HEREDITARY OPTIC NEUROPATHY (LHON), LUMEVOQ® (GS010; LENADOGENE NOLPARVOVEC), THE EARLY ACCESS TO MEDICINES SCHEME (EAMS)

This marks another important milestone in our preparations to make LUMEVOQ available to LHON patients as soon as possible.

Key Points: 
  • This marks another important milestone in our preparations to make LUMEVOQ available to LHON patients as soon as possible.
  • GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders.
  • A Promising Innovative Medicine (PIM) designation is an early indication that a medicine is a potential candidate for the EAMS scheme.
  • A PIM designation should not be regarded as a future commitment by the MHRA to license such a medicine.

Global Industrial Enzymes Market (2020 to 2027) - Featuring BASF, Novozymes and DSM Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 4, 2021
Engineering, Chemicals, Plastics, Manufacturing, Proteins, Chemistry, Enzymes, Physical sciences, Catalysis, Hydrolases, Lipase, Industrial enzymes, Cellulase, Enzyme, Biotechnology, Cross-linked enzyme aggregate

Further, the market for industrial enzymes is continuously rising, owing to the growing need for sustainable solutions.

Key Points: 
  • Further, the market for industrial enzymes is continuously rising, owing to the growing need for sustainable solutions.
  • Advancement in biotechnology, especially in protein engineering, has also brought in new probiotic products, driving the industrial enzymes market to the next level.
  • Carbohydrases, Amylases, Cellulases, Proteases and Lipases are major variants existing in the global Enzymes Market.
  • Additionally, expanding investment in the food and beverage and pharmaceutical industry is anticipated to stimulate the overall industrial enzymes market.

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Mesothelin, Proteins, Biology, Clinical medicine, Ovarian cancer, DLL3, Cancer, Canaccord Genuity, Genuity

ET / 10:10 a.m. PT; and

Key Points: 
  • ET / 10:10 a.m. PT; and
    A presentation at the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 10:30 a.m.
  • HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers.
  • HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors.
  • Harpoon has also developed a proprietary ProTriTACplatform, which applies a prodrug concept to its TriTACplatform to create a therapeutic T cell engager that remains inactive until it reaches the tumor.For additional information about Harpoon Therapeutics, please visit www.harpoontx.com .

Rain Therapeutics to Report Second Quarter 2021 Financial Results and Highlights of Recent Progress on August 10, 2021

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Biology, Proteins, Genetics, Synthetic lethality, Mdm2, Cancer

NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021.

Key Points: 
  • NEWARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN) a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the second quarter that ended June 30, 2021 and highlights of recent progress, on Tuesday, August 10, 2021.
  • On that day, management will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m.
  • Rains lead product candidate, milademetan (RAIN-32), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers.
  • In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Cerus Corporation Announces CMS Has Granted New Technology Add-On Payment for INTERCEPT Fibrinogen Complex

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, General Health, Health, Medical Supplies, Blood, Proteins, Branches of biology, Coagulation system, Acute-phase proteins, Blood proteins, Federal assistance in the United States, Healthcare reform in the United States, Cerus Corporation, Fibrinogen, Prospective payment system, Factor I deficiency

Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex within the Medicare Hospital Inpatient Prospective Payment System (IPPS).

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for INTERCEPT Fibrinogen Complex within the Medicare Hospital Inpatient Prospective Payment System (IPPS).
  • The NTAP was granted under CMS alternative NTAP pathway, which recognizes the transformative nature of products granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA).
  • The U.S. FDA granted approval of the INTERCEPT Blood System for Cryoprecipitation, which is used to produce INTERCEPT Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency, in November 2020.
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

Retrieved on: 
Monday, August 2, 2021
Enzyme kinetics, Branches of biology, Organic compounds, Chemistry, Proteins, Dipraglurant, Imidazopyridines, Organofluorides, Allosteric regulation, ASD, Dystonia, Allosteric modulator

Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.

Key Points: 
  • Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.
  • 1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

Infinipoint Launches First Device-Identity-as-a-Service (DIaaS) Solution

Retrieved on: 
Tuesday, July 27, 2021
Nutrition, Proteins, Digestible Indispensable Amino Acid Score, Business continuity planning, Articles, Emergency services, Academic disciplines

Infinipoint is pioneering the DIaaS security category and is the only solution that provides Single Sign-On (SSO) authorization integrated with risk-based policies and one-click remediation for non-compliant and vulnerable devices.

Key Points: 
  • Infinipoint is pioneering the DIaaS security category and is the only solution that provides Single Sign-On (SSO) authorization integrated with risk-based policies and one-click remediation for non-compliant and vulnerable devices.
  • Infinipoint is able to do all this in a productive way that maintains business continuity with no disruption to the workforce.
  • The Infinipoint DIaaS solution is the only one on the market built by design to meet these requirements.
  • "Infinipoint delivers the missing piece of the puzzle, and together we are delivering an innovative solution for a recent and critical problem."

Global Pea Protein Market (2020 to 2026) - by Application, Product and Regional Outlook - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Food, Beverage, Retail, Food and drink, Dietary Supplements, Nutrition, Articles, Bodybuilding supplements, Proteins, Pea protein, Meat analogue, Hydrolysate, Pea, Pigeon pea, Split pea

The "Global Pea Protein Market By Application (Dietary Supplements, Bakery Goods, Meat Substitutes, Beverage and Other Applications), By Product (Isolates, Concentrates, Textured and Hydrolysate), By Regional Outlook, Industry Analysis Report and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pea Protein Market By Application (Dietary Supplements, Bakery Goods, Meat Substitutes, Beverage and Other Applications), By Product (Isolates, Concentrates, Textured and Hydrolysate), By Regional Outlook, Industry Analysis Report and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Pea Protein Market size is expected to reach $431 Million by 2026, rising at a market growth of 18.6% CAGR during the forecast period.
  • Pea protein refers to the protein obtained from split peas which is extensively utilized in a broad range of food items like fast foods, cereals, meal replacements shakes, and energy bars.
  • Increasing demand for the product due to the rising consumer awareness with respect to the consumption of a healthy diet and living healthy lifestyles is expected to increase the growth of the global pea protein market.

ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Proteins, Biology, Amyloidosis, Neurological disorders, Structural proteins, Alzheimer's disease, Amyloid, Histopathology, TAR DNA-binding protein 43, Neurodegeneration, Promis

TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.

Key Points: 
  • TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.
  • ProMIS Chief Scientific Officer, Dr. Neil Cashman will give an oral presentation entitled: Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.
  • Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.
  • Both presentations will be available on the ProMIS website ( www.promisneurosciences.com ) after the AAIC closes on July 30.

Worldwide Pea Protein Industry to 2026 - Featuring Axiom Foods, Nutri-Pea and Sotexpro Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Retail, Agriculture, Natural Resources, Food, Beverage, Nutrition, Articles, Branches of biology, Pea protein, Proteins, Food and drink, Pea

The "Pea Protein Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Pea Protein Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global pea protein market reached a value of US$ 704 Million in 2020.
  • Looking forward, the publisher expects the global pea protein market to exhibit strong growth during the next five years.
  • Pea protein is a high-quality source of protein derived primarily from yellow peas.